前列腺癌和前列腺增生组织Hepsin表达及其临床意义

Significance of Hepsin expression in prostate cancer and benign prostatic hyperplasia tissues

目的:探讨Hepsin在前列腺癌组织中的表达,并分析其与前列腺癌临床分期及病理分级之间的关系。方法:免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结(SP)法检测68例前列腺癌、40例前列腺增生组织中Hepsin蛋白的表达,并分析其与临床分期、病理分级之间的关系。结果:Hepsin蛋白在前列腺癌组织和前列腺增生组织中阳性表达率分别为86.76%(59/68)和45.00%(18/40),差异有统计学意义,χ2=21.47,P<0.001;其阳性率在前列腺癌不同临床分期中差异有统计学意义(χ2=9.07,P=0.004),而在Glea-son评分高与低分组之间差异无统计学意义,χ2=1.15,P=0.476。结论:Hepsin可作为前列腺癌的一个诊断指标,其与前列腺癌临床分期密切相关,有可能在前列腺癌的发生发展中起重要作用。

OBJECTIVE：To observe the expression of Hepsin in prostate cancer tissues and analyse its correlation with the clinical stage and pathological grade of prostate cancer.METHODS：An immunohistochemical streptavidin-perodidase （SP） method was used to detect the expression of Hepsin in 68 prostate cancer tissures and 40 benign prostatic hyperplasia tissues.The relationship between Hepsin and the clinical-patholo gical parameters in prostate cancer was evaluated.RESULTS：There was a significant difference （χ2=21.47,P0.001） between the positive rates of Hepsin in prostate cancer （86.76%,59/68） and benign prostatic hyperplasia （45.00%,18/40）.The positive rates in different clinical stages had a significant difference （χ2=9.07,P=0.004）,but there was no difference between the high and low Gleason score groups （χ2=1.15,P=0.476）.CONCLUSIONS：Hepsin can be used as a diagnostic marker of prostate cancer.It is strongly correlated with the clinical stage and might play an important role in progression of prostate cancer.